Biostatistics

Biostatistics - Quantifying Certainty.

With Biostatistics being the heart of a clinical trial, our biostatisticians have over 15 years of experience in marketed therapeutics with NDA/BLA/PMA submissions and interactions with the FDA/EMEA and PMDA. We consult on challenging statistical issues throughout study design and analysis.

Our statisticians can lend you a hand in: 

  • Trial Design – Bayesian and Group Sequential 
  • Protocol Development 
  • Statistical Analysis Plan Development 
  • PK/PD Modelling 
  • Provide input to: Abstracts/Posters/Manuscripts 
  • Randomization Services 
  • Adaptive Design Analysis 
  • CSR support 

Statistical Modelling

We deliver excellent statistical consulting on analysis and interpretation of data using the following statistical models:

Randomization

Our team will produce mock codes for the project statistician to perform important programming for patient listings or case report tabulations. 

We can easily incorporate extensions of randomization, such as

PK-PD Modelling

Clinical data analysis requires early assessment of PK/PD data variability together with safety or efficacy data. Strategic drug development planning and smart pharmacokinetic research design can accelerate safety and efficacy. 

CONTACT US

We deliver high quality PK reports, along with additional PK/PD services, including:

  • Input to protocol, trial design and study design including sample size estimation and optimization of PK sampling.  
  • PK/PD analyses using various graphical and statistical approaches.  
  • Compartmental and Non-compartmental PK modelling.  
  • PK/PD linear and non-linear mixed modeling techniques.  
  • Statistical analyses including bioequivalence, bioavailability, drug-drug interactions, dose-proportionality and special populations.  
  • Reporting of PK/PD analysis in accordance with guidelines. Fast turnaround interim PK analyses if needed.  
  • Input into Clinical Study Reports. 

 

Statistical inputs to Protocol

Medical and Biostatistical input to a protocol is critical to ensure the statistical criteria are well defined for study conduct.  

At Genpro we:  

  • Discuss with our partner, the interim adaptation options including sample size re-estimation, and enrichment methods  
  • Develop a simulation plan for further evaluating the operating characteristics of the proposed adaptive design including power and  
    sample size  
  • Formulate study design options and run study simulations using proprietary software to evaluate and compare trial operating characteristics  
  • Consider choices of input parameters such as hazard rates of interest (e.g., Survival, response rate) and expected differences  

Once the protocol is approved during the course of the study, our statisticians will provide additional input to ensure the study is being conducted carefully.  

Below are the key areas in which statistical input becomes critical and essential:  

  • Minimizing bias: Randomization and blinding  
  • Defining desired population sets  
  • Detailed statistical methodology for efficacy and safety endpoints  
  • Hypothesis testing: describing/defining the hypotheses, significance level and analysis models  
  • Handling missing observations.  
  • Censoring  
  • Defining deviations from trial conduct  
  • Stratification  
  • Approximate time for interim analysis  

Bayesian Design

Bayesian adaptive designs are important to today’s development strategies, for high quality results and reduced patient risks along with the ability to work with small samples.  

Our team of excellent Statisticians and programmers can help you in: